Recombinant DLL3 (Rovalpituzumab Biosimilar) anticorps

N° du produit ABIN7795146

L’anticorps anti-DLL3 (Rovalpituzumab Biosimilar) Monoclonal Humanized est utilisé pour la détection de DLL3 (Rovalpituzumab Biosimilar) dans des échantillons de Humain. Il a été validé pour FACS et in vivo.

Aperçu rapide pour Recombinant DLL3 (Rovalpituzumab Biosimilar) anticorps (ABIN7795146)

Antigène: DLL3 (Rovalpituzumab Biosimilar)

Type d'anticorp: Recombinant Antibody

Reactivité: Humain

Hôte: Humanized

Clonalité: Monoclonal

Conjugué: Cet anticorp DLL3 (Rovalpituzumab Biosimilar) est non-conjugé

Application: Flow Cytometry (FACS), In vivo Studies (in vivo)

Classe de qualité: Research Grade

Détail du produit anti-DLL3 (Rovalpituzumab Biosimilar) anticorps

Expression System: Mammalian cells

Fonction: Rovalpituzumab Biosimilar, Human DLL3 Monoclonal Antibody

Attributs du produit: What is rovalpituzumab biosimilar research grade? Rovalpituzumab is a humanized IgG1-kappa monoclonal antibody against the human Delta-like 3 protein (DLL3), which is an atypical Notch ligand that has been implicated in regulation of cell development and cell fate decisions, and is a downstream target of achaetescute homolog-1 (ASCL1), suggesting its role in neuroendocrine tumorigenesis. DLL3 is expressed in more than 80 % of patients with small-cell lung cancer (SCLC) and other neuroendocrine tumors, but has little to no expression in normal tissues or non-neuroendocrine tumor types. DLL3 expression appears to be stable over time in SCLC tumors pre- and post-chemotherapy. Although DLL3 is mostly found within the Golgi apparatus under physiological conditions, it may reach the cell surface in case of overexpression and lead to Notch inhibition in cis. Rovalpituzumab tesirine (Rova-T) is a first-in-class antibody-drug conjugate (ADC) against DLL3, and composed of SC16, a humanized IgG1 antibody against DLL3, conjugated to the cytotoxic pyrrolobenzodiazepine (PBD) dimer D6.5 (SC-DR002) via a protease-cleavable linker. Rova-T selectively binds to DLL3 on target-expressing cells, is internalized, and upon proteolytic cleavage releases the toxin. PBD dimers then bind to the DNA minor groove where they form covalent adducts causing stalling of the replication forks, cell-cycle arrest at the G2-M boundary, and apoptosis. Rovalpituzumab biosimilar uses the same protein sequences as the therapeutic antibody rovalpituzumab.

Purification: Protein A or G affinity column

Pureté: >95 % by reducing SDS-PAGE

niveau d'endotoxine: < 1 EU per 1 mg of the protein by the LAL method

Immunogène: Human DLL3

Information d'application

Indications d'application: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: > 3 mg/mL

Stock: 4 °C,-20 °C

Stockage commentaire: Short time 2 to 8°C as supplied. Long time -20°C to -70°C as supplied.

Détails sur DLL3 (Rovalpituzumab Biosimilar)

Antigène: DLL3 (Rovalpituzumab Biosimilar)

Autre désignation: Rovalpituzumab Biosimilar

Classe de substances: Biosimilar